Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM
Breakthroughs in Gene Therapy for Hemophilia
Novel gene therapy for hemophilia A | Penn Today
Spark Therapeutics, Inc. (ONCE)
Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A: Molecular Therapy - Methods & Clinical Development
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
Spark Therapeutics Foresees Its Recovery (OTCMKTS:RHHBY) | Seeking Alpha
Clinical Considerations for Capsid Choice in the Development of Liver-Targeted AAV-Based Gene Transfer: Molecular Therapy - Methods & Clinical Development
Hemophilia B Gene Therapy with a High‐Specific‐Activity Factor IX Variant | Semantic Scholar
Spk-8011: Preliminary Results from a Phase 1/2 Dose Escalation Trial of an Investigational AAV-Mediated Gene Therapy for Hemophilia a - ScienceDirect
Gene Therapy for Hemophilia: Progress and Setbacks
Investigational gene therapy leads to sustained factor VIII expression in hemophilia A
Document Spark Therapeutics, Inc. 2019 Current Report 8-K
Dia 1
Spark Therapeutics, Inc. Form 8-K Current Event Report Filed 2019-01-07
Spark Therapeutics, Inc. (ONCE)
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
IJMS | Free Full-Text | Gene Therapy in Hemophilia: Recent Advances | HTML
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells | Nature Biotechnology
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for > 2 Years With Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A
Hemophilia A and B Gene Therapy SPK-8011 Advance in Clinical Trials, Spark Therapeutics Says
Hemophilia A Clinical Gene Therapy Trials (September 2020). Listed are... | Download Scientific Diagram
Spark Therapeutics Foresees Its Recovery (OTCMKTS:RHHBY) | Seeking Alpha
PDF) A Phase 1/2 Trial of Investigational Spk-8011 in Hemophilia a Demonstrates Durable Expression and Prevention of Bleeds
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM
Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A | NEJM
INVESTIGATIONAL GENE THERAPY RESEARCH STUDIES FOR HEMOPHILIA
